Skip to main content

Iconix Signs Chemogenomics Deal with Millennium

NEW YORK, Oct. 21 (GenomeWeb News) - Millennium Pharmaceuticals has selected Iconix Pharmaceuticals to provide chemogenomic profiling and analytical services for Millennium's drug discovery programs, Iconix said today.

Millennium will use Iconix's chemogenomics platform for drug candidate selection and optimization. Iconix said it would use biomarkers of drug pathology and mechanism from its Drug Signature collection of predictive biomarkers to profile Millennium's compounds.

Financial details of the agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.